menu
    • menu
    [{"orgOrder":0,"company":"HI-Bio","sponsor":"Alpha Wave Global","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Series B Financing","leadProduct":"Felzartamab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Nephrology","graph2":"Phase II","graph3":"HI-Bio","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0.10000000000000001,"dosageForm":"Infusion","sponsorNew":"HI-Bio \/ Alpha Wave Global","highestDevelopmentStatusID":"8","companyTruncated":"HI-Bio \/ Alpha Wave Global"},{"orgOrder":0,"company":"HI-Bio","sponsor":"Arch Ventures","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Financing","leadProduct":"Felzartamab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Nephrology","graph2":"Phase II","graph3":"HI-Bio","amount2":0.12,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0.12,"dosageForm":"Infusion","sponsorNew":"HI-Bio \/ Arch Ventures","highestDevelopmentStatusID":"8","companyTruncated":"HI-Bio \/ Arch Ventures"},{"orgOrder":0,"company":"HI-Bio","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Acquisition","leadProduct":"Felzartamab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Nephrology","graph2":"Phase II","graph3":"HI-Bio","amount2":1.8,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":1.8,"dosageForm":"Infusion","sponsorNew":"HI-Bio \/ Biogen","highestDevelopmentStatusID":"8","companyTruncated":"HI-Bio \/ Biogen"},{"orgOrder":0,"company":"HI-Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Felzartamab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Nephrology","graph2":"Phase II","graph3":"HI-Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"HI-Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"HI-Bio \/ Undisclosed"},{"orgOrder":0,"company":"HI-Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Felzartamab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Immunology","graph2":"Phase II","graph3":"HI-Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"HI-Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"HI-Bio \/ Undisclosed"},{"orgOrder":0,"company":"HI-Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Felzartamab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Immunology","graph2":"Phase II","graph3":"HI-Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"HI-Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"HI-Bio \/ Undisclosed"},{"orgOrder":0,"company":"HI-Bio","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Acquisition","leadProduct":"Felzartamab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Nephrology","graph2":"Phase II","graph3":"HI-Bio","amount2":1.8,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":1.8,"dosageForm":"Infusion","sponsorNew":"HI-Bio \/ Biogen","highestDevelopmentStatusID":"8","companyTruncated":"HI-Bio \/ Biogen"},{"orgOrder":0,"company":"HI-Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Felzartamab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Nephrology","graph2":"Phase II","graph3":"HI-Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"HI-Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"HI-Bio \/ Undisclosed"},{"orgOrder":0,"company":"HI-Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Felzartamab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Nephrology","graph2":"Phase II","graph3":"HI-Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"HI-Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"HI-Bio \/ Undisclosed"},{"orgOrder":0,"company":"HI-Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Felzartamab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"HI-Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HI-Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"HI-Bio \/ Undisclosed"},{"orgOrder":0,"company":"HI-Bio","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Felzartamab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Nephrology","graph2":"Phase III","graph3":"HI-Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HI-Bio \/ HI-Bio","highestDevelopmentStatusID":"10","companyTruncated":"HI-Bio \/ HI-Bio"},{"orgOrder":0,"company":"HI-Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Felzartamab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Nephrology","graph2":"Phase II","graph3":"HI-Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HI-Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"HI-Bio \/ Undisclosed"},{"orgOrder":0,"company":"HI-Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"MOR202","moa":"Lymphocyte differentiation antigen CD38","graph1":"Nephrology","graph2":"Phase II","graph3":"HI-Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"HI-Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"HI-Bio \/ Undisclosed"},{"orgOrder":0,"company":"HI-Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"MOR202","moa":"Lymphocyte differentiation antigen CD38","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"HI-Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"HI-Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"HI-Bio \/ Undisclosed"},{"orgOrder":0,"company":"HI-Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"HIB210","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"HI-Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HI-Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"HI-Bio \/ Undisclosed"},{"orgOrder":0,"company":"HI-Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"HIB210","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"HI-Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HI-Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"HI-Bio \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by HI-Bio

    Menu

    HI-Bio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            HI-Bio

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            HI-Bio

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Felzartamab

                            Therapeutic Area : Nephrology

                            Study Phase : Phase III

                            Recipient : Biogen

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)

                            Details : Felzartamab is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Glomerulonephritis, IGA.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            April 20, 2025

                            Lead Product(s) : Felzartamab

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase III

                            Recipient : Biogen

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            HI-Bio

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            HI-Bio

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Felzartamab

                            Therapeutic Area : Nephrology

                            Study Phase : Phase II

                            Sponsor : Biogen

                            Deal Size : $1,800.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Biogen Completes Acquisition of Human Immunology Biosciences

                            Details : Through the acquisition, Biogen will have access to pipeline a range of immune-mediated diseases, including MOR202 (felzartamab), being evaluated for treating primary membranous nephropathy.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : $1,150.0 million

                            July 02, 2024

                            Lead Product(s) : Felzartamab

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase II

                            Sponsor : Biogen

                            Deal Size : $1,800.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            HI-Bio

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            HI-Bio

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Felzartamab

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            HI-Bio Reports Positive Phase 2 Results of Felzartamab in Kidney Transplant Patients

                            Details : MOR202 (felzartamab) is an investigational monoclonal antibody designed to specifically target and deplete CD38+ cells. It is being evaluated for late AMR in kidney transplant recipients.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            May 25, 2024

                            Lead Product(s) : Felzartamab

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            HI-Bio

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            HI-Bio

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Felzartamab

                            Therapeutic Area : Nephrology

                            Study Phase : Phase II

                            Sponsor : Biogen

                            Deal Size : $1,800.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Biogen Expands Immunology Portfolio By Acquiring Human Immunology Biosciences

                            Details : Through acquisition, Biogen gains access to pipeline-in-a-product for immune-mediated diseases, including MOR202 (felzartamab) for treating primary membranous nephropathy.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : $1,150.0 million

                            May 22, 2024

                            Lead Product(s) : Felzartamab

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase II

                            Sponsor : Biogen

                            Deal Size : $1,800.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            HI-Bio

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            HI-Bio

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Felzartamab

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            HI-Bio Receives FDA Orphan Drug Designation for Felzartamab in Kidney Transplants

                            Details : MOR202 (felzartamab) is an investigational monoclonal antibody targeting CD38, being evaluated for treating antibody-mediated rejection in kidney transplant recipients.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            March 21, 2024

                            Lead Product(s) : Felzartamab

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            HI-Bio

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            HI-Bio

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Felzartamab

                            Therapeutic Area : Nephrology

                            Study Phase : Phase II

                            Sponsor : Alpha Wave Global

                            Deal Size : $95.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            HI-Bio Announces $95 Million Series B Financing for Targeted Therapies in Immune Diseases

                            Details : The net proceeds will be used to advance MOR202 (felzartamab), a monoclonal antibody targeting CD38, through clinical readouts in multiple indications and preparation for registrational studies.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            January 04, 2024

                            Lead Product(s) : Felzartamab

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase II

                            Sponsor : Alpha Wave Global

                            Deal Size : $95.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            HI-Bio

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            HI-Bio

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Felzartamab

                            Therapeutic Area : Nephrology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            HI-Bio Announces Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration for...

                            Details : MOR 202 (felzartamab) is a monoclonal antibody directed against CD38, it has the potential to deplete CD38+ plasma cells while leaving other functionally important plasma cells intact. it is under phase 2 clinical development for the treatment of PMN.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            October 31, 2023

                            Lead Product(s) : Felzartamab

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            HI-Bio

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            HI-Bio

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Felzartamab

                            Therapeutic Area : Nephrology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Learn More About the Safety and Effects of Felzartamab in Adults With Lupus Nephritis Aged 18 to 75...

                            Details : Felzartamab is a Antibody drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Lupus Nephritis.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            October 03, 2023

                            Lead Product(s) : Felzartamab

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            HI-Bio

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            HI-Bio

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HIB210

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            HI-Bio Initiates Healthy Volunteer Study of HIB210 for Immune-Mediated Diseases

                            Details : HIB210 is an investigational therapeutic human monoclonal antibody directed against complement factor C5a receptor 1 (C5aR1). C5aR1 is responsible for guiding and activating myeloid cells and is highly expressed on neutrophils, monocytes and macrophages.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 11, 2023

                            Lead Product(s) : HIB210

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            HI-Bio

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            HI-Bio

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HIB210

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of Safety and Drug Levels of HIB210 in Healthy Volunteers

                            Details : HIB210 is a Other Large Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Immune System Diseases.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 03, 2023

                            Lead Product(s) : HIB210

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth